๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

โœ Scribed by Tefferi, A; Pardanani, A; Lim, K-H; Abdel-Wahab, O; Lasho, T L; Patel, J; Gangat, N; Finke, C M; Schwager, S; Mullally, A

Book ID
109887078
Publisher
Nature Publishing Group
Year
2009
Tongue
English
Weight
164 KB
Volume
23
Category
Article
ISSN
0887-6924

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Leukemogenic risk of hydroxyurea therapy
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
โœ Nand, Sucha; Stock, Wendy; Godwin, John; Fisher, Susan Gross ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 417 KB ๐Ÿ‘ 2 views

In polycythemia Vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%. This risk has been estimated to be 1-5.9% with hydroxyurea (HU) therapy. When compared with historical controls, the risk with use of HU does not a